Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 343

1.

A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis.

Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, Ringner-Nackter L, Higgs CJ, Herold BC, Gazzard BG, Boffito M.

Clin Pharmacol Ther. 2014 Sep;96(3):314-23. doi: 10.1038/clpt.2014.118. Epub 2014 May 26.

PMID:
24862215
2.

Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.

Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG, Nelson M.

AIDS. 2013 Oct 23;27(16):2551-7. doi: 10.1097/QAD.0b013e32836381cc.

PMID:
23736152
3.

Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned.

Martin TC, Scourfield A, Rockwood N, Martin NK, Patel N, Nelson M, Gazzard BG.

HIV Med. 2013 Mar;14(3):161-6. doi: 10.1111/j.1468-1293.2012.01047.x. Epub 2012 Sep 21.

4.

Short communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV type 1+ individuals with high plasma viral load.

Gregson JN, Kuri-Cervantes L, Mela CM, Gazzard BG, Bower M, Goodier MR.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):84-8. doi: 10.1089/AID.2011.0397. Epub 2012 Sep 25.

5.

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ, Winston A, Fox J, Orkin C, Herieka EA, Ainsworth JG, Post FA, Wansbrough-Jones M, Kelleher P; Hydroxychloroquine Trial Team.

JAMA. 2012 Jul 25;308(4):353-61. doi: 10.1001/jama.2012.6936.

6.

Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010.

Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG, Imami N.

PLoS One. 2012;7(2):e29844. doi: 10.1371/journal.pone.0029844. Epub 2012 Feb 20.

7.

Reduced T(H)1/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection.

Clark S, Page E, Ford T, Metcalf R, Pozniak A, Nelson M, Henderson DC, Asboe D, Gotch F, Gazzard BG, Kelleher P.

J Allergy Clin Immunol. 2011 Oct;128(4):838-846.e5. doi: 10.1016/j.jaci.2011.05.025. Epub 2011 Jul 13.

PMID:
21745684
8.

British HIV Association and Children's HIV Association position statement on infant feeding in the UK 2011.

Taylor GP, Anderson J, Clayden P, Gazzard BG, Fortin J, Kennedy J, Lazarus L, Newell ML, Osoro B, Sellers S, Tookey PA, Tudor-Williams G, Williams A, de Ruiter A; BHIVA/CHIVA Guidelines Writing Group.

HIV Med. 2011 Aug;12(7):389-93. doi: 10.1111/j.1468-1293.2011.00918.x. Epub 2011 Mar 21.

9.

The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy.

Waters LJ, Scourfield AT, Marcano M, Gazzard BG, Bower M, Nelson M, Stebbing J.

Clin Infect Dis. 2011 Mar 1;52(5):671-3. doi: 10.1093/cid/ciq198.

PMID:
21292672
10.

Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment.

Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR.

Aliment Pharmacol Ther. 2011 Jan;33(1):115-26. doi: 10.1111/j.1365-2036.2010.04499.x. Epub 2010 Oct 29.

11.

Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.

Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF, Moyle GJ, Jackson AA, Gazzard BG.

Br J Nutr. 2009 Oct;102(7):1038-46. doi: 10.1017/S0007114509338817. Epub 2009 Jun 1.

PMID:
19480729
12.

The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.

Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):140-6. doi: 10.1097/QAI.0b013e3181a56e81.

PMID:
19352201
13.

Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individuals.

Gregson JN, Steel A, Bower M, Gazzard BG, Gotch FM, Goodier MR.

AIDS. 2009 Jan 2;23(1):29-34. doi: 10.1097/QAD.0b013e3283199780.

PMID:
19050383
14.

Controversies in current treatment guidelines.

Gazzard BG.

J HIV Ther. 2008 Mar;13(1):1-3. Review. No abstract available.

PMID:
18953266
15.

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.

Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, Churchill D, Cromarty B, Das S, Fisher M, Freedman A, Geretti AM, Johnson M, Khoo S, Leen C, Nair D, Peters B, Phillips A, Pillay D, Pozniak A, Walsh J, Wilkins E, Williams I, Williams M, Youle M; BHIVA Treatment Guidelines Writing Group.

HIV Med. 2008 Oct;9(8):563-608. doi: 10.1111/j.1468-1293.2008.00636.x. No abstract available.

16.

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.

Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team.

HIV Med. 2008 Oct;9(8):667-72. doi: 10.1111/j.1468-1293.2008.00618.x. Epub 2008 Jul 8.

17.

Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.

Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S.

J Interferon Cytokine Res. 2008 Feb;28(2):89-100. doi: 10.1089/jir.2007.0064.

PMID:
18279104
18.

CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy.

Steel A, John L, Shamji MH, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.

HIV Med. 2008 Feb;9(2):118-25. doi: 10.1111/j.1468-1293.2007.00528.x.

19.

Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals.

Mela CM, Steel A, Lindsay J, Gazzard BG, Gotch FM, Goodier MR.

AIDS. 2007 Oct 18;21(16):2177-82.

PMID:
18090044
20.

Guillain--Barre syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection.

Teo EC, Azwra A, Jones RL, Gazzard BG, Nelson M.

J HIV Ther. 2007 Sep;12(3):62-3. No abstract available.

PMID:
17962793
21.

HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.

Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.

Antivir Ther. 2007;12(6):971-5.

PMID:
17926652
22.

When should antiretroviral therapy for HIV be started?

Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD.

BMJ. 2007 Jan 13;334(7584):76-8. Review. No abstract available.

23.

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel.

Top HIV Med. 2006 Aug-Sep;14(3):827-43.

PMID:
17016878
24.

Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy.

Palmieri C, Dhillon T, Thirlwell C, Newsom-Davis T, Young AM, Nelson M, Gazzard BG, Bower M.

HIV Med. 2006 Jul;7(5):291-3.

25.

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA panel.

JAMA. 2006 Aug 16;296(7):827-43.

PMID:
16905788
26.

The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe.

Mazhar D, Stebbing J, Lewis R, Nelson M, Gazzard BG, Bower M.

Blood. 2006 Apr 15;107(8):3412-4. No abstract available.

PMID:
16597601
27.

Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.

Gazzard BG.

Expert Opin Pharmacother. 2006 Apr;7(6):793-802. Review.

PMID:
16556093
28.

Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.

Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-J─ârvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):565-72.

PMID:
16284533
29.

Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.

Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.

HIV Med. 2005 Nov;6(6):396-402.

30.

Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection.

Burton CT, Nelson MR, Hay P, Gazzard BG, Gotch FM, Imami N.

Clin Exp Immunol. 2005 Nov;142(2):354-61.

31.

Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy.

Mela CM, Burton CT, Imami N, Nelson M, Steel A, Gazzard BG, Gotch FM, Goodier MR.

AIDS. 2005 Nov 4;19(16):1761-9.

PMID:
16227783
32.

Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin.

Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, Gazzard BG, Nelson MR.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):41-6.

PMID:
16123680
33.

Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma.

Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, Dhillon T, Holmes P, Gazzard BG, Stebbing J.

J Clin Oncol. 2005 Aug 1;23(22):5224-8.

PMID:
16051964
34.

Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis.

Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG.

Antivir Ther. 2005;10(3):417-22.

PMID:
15918332
36.

The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.

Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG.

Antivir Ther. 2005;10(2):357-61.

PMID:
15865231
37.

The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic.

Fox PA, Seet JE, Stebbing J, Francis N, Barton SE, Strauss S, Allen-Mersh TG, Gazzard BG, Bower M.

Sex Transm Infect. 2005 Apr;81(2):142-6.

38.

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection.

Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG.

J Infect Dis. 2005 Mar 15;191(6):866-72. Epub 2005 Feb 11.

PMID:
15717260
39.

Rising rates of HIV infection.

Robinson AJ, Gazzard BG.

BMJ. 2005 Feb 12;330(7487):320-1. No abstract available.

40.

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL.

AIDS. 2004 Jun 18;18(9):1291-7.

PMID:
15362661
41.

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA.

JAMA. 2004 Jul 14;292(2):251-65.

PMID:
15249575
42.

Does atazanavir cause lipodystrophy?

Gazzard BG, Moyle G.

J HIV Ther. 2004 May;9(2):41-4. Review.

PMID:
15238875
43.

Fever in the recently returned HIV infected traveller.

Birnie A, Gazzard BG, Bacon C, Dogan A, Shaw PJ, Miller RF.

Sex Transm Infect. 2004 Apr;80(2):86-90.

44.

Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated.

Portsmouth S, Imami N, Pires A, Stebbing J, Hand J, Nelson M, Gotch F, Gazzard BG.

HIV Med. 2004 Jan;5(1):26-9.

45.

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.

Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J, vant' Klooster GA.

AIDS. 2003 Dec 5;17(18):F49-54.

PMID:
14685068
46.

Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.

Stebbing J, Wildfire A, Portsmouth S, Powles T, Thirlwell C, Hewitt P, Nelson M, Patterson S, Mandalia S, Gotch F, Gazzard BG, Bower M.

Ann Oncol. 2003 Nov;14(11):1660-6.

PMID:
14581275
47.

The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients.

Gilleece Y, Torti C, Mandalia S, Gazzard BG, Pillay D, Pozniak AL.

HIV Med. 2003 Oct;4(4):305-10.

48.
49.

Successful treatment of acute haemorrhagic cytomegalovirus colitis with ganciclovir in an individual without overt immunocompromise.

Patel SM, Cohen P, Pickering MC, Gazzard BG, Andreyev J.

Eur J Gastroenterol Hepatol. 2003 Sep;15(9):1055-60. Review. No abstract available.

PMID:
12923383
50.

Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection.

Morlese JF, Orkin CM, Abbas R, Burton C, Qazi NA, Nelson MR, Imami N, Gazzard BG.

AIDS. 2003 Jun 13;17(9):1411-3. No abstract available.

PMID:
12799572

Supplemental Content

Loading ...
Support Center